Developing Thermally Stable Dry Powder Vaccine Platforms Via Spray Drying Tailored for Inhalation Delivery

疫苗开发方面的创新通过追求新的和改进的生物制品，并通过改变其配方和制造来重新设想新的递送途径，极大地造福于公众健康。拟议的研究将推动跨学科科学家团队在设计新的抗击结核病和流感感染的热稳定疫苗平台方面取得的最新进展，其中对温度敏感的生物制剂将通过在合适的载体中封装来稳定，从而消除了对昂贵且往往无法获得的制冷设备在储存和运输中的必要性。拟议的项目结合了化学工程和生物医学的专业知识，以了解和实施与工业相关的干燥技术，这些技术将生产耐热干粉疫苗，以保持其原始液体形式的免疫增强效力，但现在可以在室温下储存3个月而不会失去活性，而液体效力损失不到1周。在优化的条件下对疫苗粉末进行喷雾干燥，可以产生一种专为吸入而设计的产品，提高了它们对结核病和流感等肺部传播感染的有效性，同时避免了在接种前在液体介质中重新构建干燥疫苗的复杂物流。这项研究将产生耐热粉末结核病和流感疫苗的最佳例子，将它们的物理和生物特性与人类呼吸系统中颗粒形成和颗粒空气动力学的工程原理联系起来。新的知识将被转让给适当的药学专家，以造福加拿大的公共卫生。

Innovations in vaccine development greatly benefit public health, by pursuing new andimproved biologics, and re-envisioning new delivery routes though changes in theirformulation and manufacture. The proposed research will advance recent progress made byan interdisciplinary team of scientists in designing new thermally stable vaccine platformstargeted against tuberculosis and influenza infection, where the temperature sensitivebiologics will be stabilized by encapsulation in suitable carriers, thereby removing thenecessity for costly and often unavailable refrigeration equipment in their storage andtransport. The proposed project brings together chemical engineering and biomedicalexpertise to understand and implement industrially relevant drying techniques that willproduce thermostable dry powder vaccines retaining their immune-boosting potency as seenin their original liquid form, yet now can be stored at room temperature for 3 months withoutloss in activity whereas liquid losses in potency occur in less than 1 week. Spray-drying thesevaccine powders under optimized conditions results in a product designed for delivery to thelung by inhalation, boosting their effectiveness against lung-borne infections like tuberculosisand influenza, while avoiding the complex logistics of re-constituting dried vaccines in liquidmedia prior to administration. The research will produce optimal examples of thermostabledry powder tuberculosis and influenza vaccines, relating their physical and biologicalproperties to engineering principles on particle formation and particle aerodynamics in thehuman respiratory system. The new knowledge will be transferred to appropriatepharmaceutical experts for the benefit of Canadas public health.